You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly has escalated its legal offensive against compounding pharmacies accused of selling unauthorized copies of its blockbuster diabetes and weight-loss drugs containing tirzepatide, the active ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Merck Animal Health is investing $895 million in its Kansas facility. Novo Nordisk anticipates Wegovy sales recovery ...

Houston Chronicle reporter Julian Gill discusses his recent investigation on Eli Lilly targeting a Houston-based pharmacy ...

Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack ...

• What Eli Lilly’s chief executive said about Trump’s plans to repatriate supply chains to America • The scale of Lilly’s ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.